Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Ketamine and Dexmedetomidine for Autism Spectrum Disorder
NCT03434366Phase 2Suspended
- Start
- Jan 2018
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ketamine in Autism Spectrum Disorder (ASD). Started Jan 2018; status: suspended.
02
Drugs
ketamine
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03434366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03434366.